呼吸肌训练疗法能否有效治疗中风后的阻塞性睡眠呼吸暂停综合征?:一项系统评价与荟萃分析方案
Can respiratory muscle training therapy effectively manage obstructive sleep apnea syndrome after stroke?: A protocol of systematic review and meta-analysis.
作者信息
Guo Shu-Wen, Dai Chang-Fei, Yu Liang, Zhao Xiong-Fei
机构信息
Department of Neurology-Neuroelectrophysiology, Cardio-Crebrovascular Disease Hospital of Meishan, Meishan, Sichuan.
Department of Neurology, Xianyang Hospital of Yan'an University, Xianyang.
出版信息
Medicine (Baltimore). 2020 Jun 12;99(24):e20589. doi: 10.1097/MD.0000000000020589.
BACKGROUND
This study will explore the effectiveness and safety of respiratory muscle training therapy (RMTT) for the treatment of patients with obstructive sleep apnea syndrome (OSAS) after stroke.
METHODS
In this study, we will systematically and comprehensively search Cochrane Library, PubMed, EMBASE, WANGFANG, VIP, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure for relevant literature from their inception to March 1, 2020 without any limitations to language and publication status. We will consider any randomized controlled trials focusing on the effectiveness and safety of RMTT for the treatment of patients with OSAS after stroke. The study quality will be checked using Cochrane risk of bias tool, and statistical analysis will be performed utilizing RevMan 5.3 software.
RESULTS
This study will summarize and synthesize the current evidence of RMTT for the treatment of patients with OSAS following stroke.
CONCLUSION
The findings of this study will assess the present evidence for the benefits and harms of RMTT for treating OSAS after stroke, and will inform clinical practice and future research.
PROSPERO REGISTRATION NUMBER
PROSPERO CRD42020170355.
背景
本研究将探讨呼吸肌训练疗法(RMTT)对中风后阻塞性睡眠呼吸暂停综合征(OSAS)患者的治疗效果及安全性。
方法
在本研究中,我们将系统全面地检索Cochrane图书馆、PubMed、EMBASE、万方、维普、中国生物医学文献数据库和中国知网,检索自各数据库建库至2020年3月1日的相关文献,对语言和出版状态无任何限制。我们将纳入任何关注RMTT治疗中风后OSAS患者有效性和安全性的随机对照试验。使用Cochrane偏倚风险工具检查研究质量,并利用RevMan 5.3软件进行统计分析。
结果
本研究将总结并综合目前RMTT治疗中风后OSAS患者的证据。
结论
本研究结果将评估目前RMTT治疗中风后OSAS的利弊证据,并为临床实践和未来研究提供参考。
国际前瞻性注册系统登记号
PROSPERO CRD42020170355。